Bolt Biotherapeutics, Inc. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
Bolt Biotherapeutics, Inc. (BOLT) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2026-03-12
- Bolt Biotherapeutics, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2022-12-31 was $0.00.
- Bolt Biotherapeutics, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2021-12-31 was -$227.00K.
- Bolt Biotherapeutics, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2021-09-30 was $0.00, a 100.00% decline year-over-year.
- Bolt Biotherapeutics, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2020-12-31 was $0.00.
- Bolt Biotherapeutics, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- Bolt Biotherapeutics, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2024 was $6.40M.
- Bolt Biotherapeutics, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- Bolt Biotherapeutics, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $852.00K, a 94.19% decline from fiscal 2021.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-12 | |||
| 2024-12-31 | $6.40M 10-K · filed 2026-03-12 | |||
| 2023-12-31 | $0.00 10-K · filed 2025-03-24 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $852.00K 10-K · filed 2024-03-21 | ||
| 2022-09-30 | $852.00K 10-Q · filed 2023-11-09 | |||
| 2021-12-31 | -$227.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | -$227.00K derived: sum of 2 quarters · filed 2023-03-29 | $14.66M 10-K · filed 2023-03-29 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $14.88M 10-Q · filed 2022-11-10 | ||
| 2021-06-30 | $14.88M 10-Q · filed 2022-08-10 | |||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | $3.76M derived: sum of 2 quarters · filed 2022-03-30 | $3.83M derived: sum of 3 quarters · filed 2022-03-30 | $4.08M 10-K · filed 2022-03-30 |
| 2020-09-30 | $3.76M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $3.83M derived: sum of 2 quarters · filed 2021-11-09 | $4.08M 10-Q · filed 2021-11-09 | |
| 2020-06-30 | $70.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $324.00K 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | $254.00K 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |